Condition: Sarcoma, Soft Tissue
Interventions: Drug: 609A; Drug: doxorubicin hydrochloride
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Not yet recruiting
Feeds
5250 items (5250 unread) in 74 feeds
Acinar Cell Carcinoma
(12 unread)
Acinic Cell Carcinoma
(18 unread)
Adenoid Cystic Carcinoma
(90 unread)
Adrenal Gland Cancer
(452 unread)
Ampulla Of Vater
(60 unread)
Anal Cancer
(494 unread)
Angiosarcoma
(130 unread)
Appendix Cancer
(85 unread)
Bile Duct Cancer
(664 unread)
Brain and CNS
(597 unread)
Carcinoid
(153 unread)
Endocrine/Neuroendocrine
(652 unread)
Gall Bladder Cancer
(338 unread)
Hemangioendothelioma
(117 unread)
Hepatoblastoma
(151 unread)
Pancreas
(60 unread)
Phyllodes
(26 unread)
PMP and Mucinous Tumors
(39 unread)
Rhabdomyosarcoma
(187 unread)
Sarcoma
(925 unread)
Trial - Sarcoma (43 unread)
-
A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma
Posted: November 30th, 2021, 3:00pm GMT
-
Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas
Posted: November 23rd, 2021, 3:00pm GMT
Conditions: Soft Tissue Sarcoma; Bone Tumors; Small Round-cell Sarcomas
Intervention: Drug: Trabectedin
Sponsor: Grupo Espanol de Investigacion en Sarcomas
Recruiting -
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Posted: November 23rd, 2021, 3:00pm GMT
Conditions: SCLC; Malignant Melanoma; Sarcoma
Intervention: Drug: GD2-SADA:177Lu-DOTA Complex
Sponsor: Y-mAbs Therapeutics
Not yet recruiting -
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
Posted: November 23rd, 2021, 3:00pm GMT
Conditions: Cancer; Cancer Metastatic; Neoplasms; Breast Cancer; Lung Cancer; Thyroid Cancer; Lymphoma; Lymphoma, Non-Hodgkin; Hodgkin Lymphoma; Leukemia; Sarcoma; Skin Cancer; Bone Cancer; Gynecologic Cancer; Pancreas Cancer; Multiple Myeloma; Colorectal Cancer; Gastrointestinal Cancer; Prostate Cancer; Glioblastoma; Brain Cancer; Head and Neck Cancer
Intervention: Behavioral: Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
Sponsors: Cedars-Sinai Medical Center; Walter Reed National Military Medical Center
Not yet recruiting -
A Phase I Trial of CCT301-38 in Patients With Relapsed or Refractory AXL Positive Sarcomas
Posted: November 22nd, 2021, 3:00pm GMT
Condition: SAR
Intervention: Biological: CCT301-38
Sponsors: Shanghai PerHum Therapeutics Co., Ltd.; Shanghai Zhongshan Hospital
Recruiting -
Assessment of CA 19-9 in Patients' With Thyroid Malignancies
Posted: November 18th, 2021, 3:00pm GMT
Condition: Thyroid Cancer
Intervention: Diagnostic Test: Laboratory investigations for control: a-Complete blood count. b-Liver function test. c-kidney function test. d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.
Sponsor: Sohag University
Not yet recruiting -
A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma
Posted: November 16th, 2021, 3:00pm GMT
Condition: Soft Tissue Sarcoma
Interventions: Drug: Anlotinib hydrochloride capsule; Drug: Epirubicin; Drug: Arotinib hydrochloride capsule placebo
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Not yet recruiting -
Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors
Posted: November 16th, 2021, 3:00pm GMT
Conditions: Sarcoma; Melanoma
Intervention: Radiation: Pro-GRID
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting -
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
Posted: November 15th, 2021, 3:00pm GMT
Conditions: Hepatocellular Carcinoma; Squamous Cell Carcinoma of the Lung; Merkel Cell Carcinoma; Liposarcoma
Intervention: Biological: CAR-GPC3 T Cells
Sponsors: SOTIO, LLC; SOTIO Biotech
Not yet recruiting -
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Posted: November 11th, 2021, 3:00pm GMT
Conditions: Soft Tissue Sarcoma; Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Leiomyosarcoma; Liposarcoma; Angiosarcoma; Synovial Sarcoma; Rhabdomyosarcoma; Spindle Cell Sarcoma; High Grade Sarcoma; Bone Sarcoma; Osteosarcoma; Ewing Sarcoma of Bone
Interventions: Drug: Gemcitabine; Drug: 9-ING-41; Drug: Docetaxel
Sponsors: Brown University; Actuate Therapeutics
Not yet recruiting -
ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma
Posted: November 11th, 2021, 3:00pm GMT
Conditions: Leiomyosarcoma; Liposarcoma
Intervention: Drug: ATX-101
Sponsor: Columbia University
Not yet recruiting -
Sarcomas and DDR-Inhibition; a Combined Modality Study
Posted: November 10th, 2021, 3:00pm GMT
Condition: Soft Tissue Sarcoma Adult
Interventions: Combination Product: AZD1390 + radiotherapy; Combination Product: AZD7648 + radiotherapy
Sponsors: The Netherlands Cancer Institute; Leiden University Medical Center; University Medical Center Nijmegen
Not yet recruiting -
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
Posted: November 10th, 2021, 3:00pm GMT
Condition: Solid Tumor, Adult
Intervention: Drug: EVT801
Sponsor: Kazia Therapeutics Limited
Recruiting -
HIFU Ablation of Soft Tissue Sarcoma
Posted: November 8th, 2021, 3:00pm GMT
Conditions: Soft Tissue Sarcoma; Desmoid; Abdominal
Interventions: Device: High Intensity Focused Ultrasound Ablation; Diagnostic Test: Tumour Biopsy and Venous Blood Tests
Sponsors: Oxford University Hospitals NHS Trust; Surgical Intervention Trials Unit (trial oversight); NIHR Direct Delivery Team (implementation); Oxford Radiology Research Unit (implementation)
Not yet recruiting -
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
Posted: November 5th, 2021, 2:00pm GMT
Condition: Soft Tissue Sarcoma
Interventions: Radiation: Conventional Fractionated; Radiation: Hypofractionated
Sponsor: University of Wisconsin, Madison
Recruiting -
Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma
Posted: November 4th, 2021, 2:00pm GMT
Condition: Sarcoma
Intervention: Drug: Surufatinib
Sponsor: Sun Yat-sen University
Not yet recruiting -
Integrated Clinical-radiological Analysis of Hypoxia Markers in Pediatric Osteosarcomas
Posted: November 4th, 2021, 2:00pm GMT
Condition: Osteosarcoma in Children
Intervention:
Sponsor: University Hospital, Strasbourg, France
Recruiting -
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Posted: November 4th, 2021, 2:00pm GMT
Conditions: Breast Cancer, NOS; CNS Primary Tumor, NOS; Cervical Cancer, NOS; Colorectal Cancer, NOS; Leukemia, NOS; Lymphoma, NOS; Miscellaneous Neoplasm, NOS; Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS; Testicular Nonseminomatous Germ Cell Tumor, NOS; Thyroid Cancer, NOS; Melanoma; Bone Cancer, NOS
Intervention: Other: Questionnaires
Sponsor: Eastern Cooperative Oncology Group
Recruiting -
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Posted: November 3rd, 2021, 2:00pm GMT
Conditions: Ependymoma; Medulloblastoma; Glioblastoma; Primitive Neuroectodermal Tumor (PNET)
Interventions: Drug: Ibrutinib; Drug: Indoximod; Drug: Cyclophosphamide; Drug: Etoposide
Sponsors: Theodore S. Johnson; Augusta University
Not yet recruiting -
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Hepatocellular Carcinoma
Posted: November 2nd, 2021, 2:00pm GMT
Conditions: Liver Cancer; Rhabdomyosarcoma; Malignant Rhabdoid Tumor, Somatic; Liposarcoma; Wilms Tumor; Yolk Sac Tumor
Interventions: Genetic: CATCH T cells; Drug: Cytoxan; Drug: Fludara
Sponsors: Baylor College of Medicine; Center for Cell and Gene Therapy, Baylor College of Medicine; Houston Methodist Hospital, TX
Not yet recruiting -
A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
Posted: October 29th, 2021, 2:00pm GMT
Condition: Metastatic Soft-tissue Sarcoma
Interventions: Drug: NOX66; Drug: Doxorubicin
Sponsor: Noxopharm Limited
Not yet recruiting -
Lurbinectedin + Doxorubicin In Leiomyosarcoma
Posted: October 29th, 2021, 2:00pm GMT
Conditions: Advanced Soft-tissue Sarcoma; Metastatic Soft-tissue Sarcoma; Advanced Leiomyosarcoma; Leiomyosarcoma Metastatic
Interventions: Drug: Lurbinectedin; Drug: Doxorubicin
Sponsors: Massachusetts General Hospital; Jazz Pharmaceuticals
Not yet recruiting -
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Posted: October 26th, 2021, 2:00pm GMT
Conditions: Solid Tumor; Lymphoma; Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Non-rhabdomyosarcoma Soft Tissue Sarcoma
Intervention: Drug: Surufatinib in combination with Gemcitabine
Sponsor: Hutchison Medipharma Limited
Not yet recruiting -
The Prognostic Value of Serum Biomarkers in Osteosarcoma
Posted: October 26th, 2021, 2:00pm GMT
Condition: Osteosarcoma
Intervention: Other: case series review of clinical data
Sponsor: Istituto Ortopedico Rizzoli
Recruiting -
Study of LVGN3616 and LVGN6501±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
Posted: October 13th, 2021, 2:00pm GMT
Conditions: Metastatic Esophageal; Gastric Cancer; Metastatic Head and Neck Carcinoma; Metastatic Hepatocellular Carcinoma; Metastatic HPV Related Solid Tumors; Metastatic Ovarian Carcinoma; Metastatic Soft Tissue Sarcoma; Metastatic Uveal Melanoma
Interventions: Drug: LVGN3616 + LVGN6051 + Nab-Paclitaxel; Drug: LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; Drug: LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel; Drug: LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
Sponsors: M.D. Anderson Cancer Center; Lyvgen Biopharma Holdings Limited
Recruiting -
Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements.
Posted: August 27th, 2021, 2:00pm GMT
Conditions: Ewing Sarcoma of Bone; Osteosarcoma
Interventions: Drug: Tranexamic acid injection; Other: Saline
Sponsor: Children's Cancer Hospital Egypt 57357
Recruiting -
Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable Angiosarcoma
Posted: April 26th, 2021, 2:00pm GMT
Condition: Angiosarcoma Metastatic
Intervention: Drug: Abraxane combined with liposomal doxorubicin
Sponsor: Sun Yat-sen University
Recruiting -
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Posted: April 21st, 2021, 2:00pm GMT
Conditions: Minimal Residual Disease; KRAS G12D; KRAS G12R; NRAS G12D; NRAS G12R; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Cholangiocarcinoma; Bile Duct Cancer; Gallbladder Carcinoma
Intervention: Drug: ELI-002 2P
Sponsor: Elicio Therapeutics
Recruiting -
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Posted: January 20th, 2021, 3:00pm GMT
Conditions: Liver Cancer; Rhabdomyosarcoma; Malignant Rhabdoid Tumor; Liposarcoma; Wilms Tumor; Yolk Sac Tumor
Interventions: Genetic: CARE T cells; Drug: Cytoxan; Drug: Fludara
Sponsors: Baylor College of Medicine; Center for Cell and Gene Therapy, Baylor College of Medicine
Not yet recruiting -
Adriamycin and Ifosfamide Combined With Sintilimab
Posted: October 19th, 2020, 2:00pm GMT
Condition: Soft Tissue Sarcoma
Intervention: Drug: Sintilimab plus chemotherapy
Sponsor: Sun Yat-sen University
Recruiting -
Swiss Sarcoma Network: Prediction Model for Patient Selection in Sarcoma Care
Posted: March 9th, 2020, 2:00pm GMT
Condition: Sarcoma
Intervention:
Sponsors: Kantonsspital Winterthur KSW; SwissSarcomaNetwork
Recruiting -
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
Posted: December 13th, 2019, 3:00pm GMT
Conditions: Metastatic Sarcoma; Recurrent Sarcoma; Resectable Sarcoma
Interventions: Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Device: Drug Delivery Microdevice; Drug: Everolimus; Biological: Ganitumab; Drug: Ifosfamide; Drug: Irinotecan; Drug: Pazopanib; Drug: Polyethylene Glycol; Drug: Temozolomide; Drug: Temsirolimus; Procedure: Therapeutic Conventional Surgery; Drug: Vincristine
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Not yet recruiting -
The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors
Posted: August 22nd, 2018, 2:00pm GMT
Conditions: Ovarian Cancer; Fallopian Tube Adenocarcinoma; Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Malignant Ovarian Brenner Tumor; Ovarian Adenocarcinoma; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Transitional Cell Carcinoma
Interventions: Other: Exercise Counseling; Other: Aerobic Exercise; Other: Physiological Support; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Other: Best Practice
Sponsors: University of Washington; National Cancer Institute (NCI)
Recruiting -
Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers
Posted: May 29th, 2018, 2:00pm GMT
Conditions: Glioblastomas; Sarcoma; Astrocytoma; Brain Cancer; Leukemia
Interventions: Behavioral: Enhanced Mindfulness Intervention; Behavioral: Psychoeducation
Sponsor: National Cancer Institute (NCI)
Recruiting -
FAZA PET/MRI Sarcoma
Posted: February 1st, 2018, 3:00pm GMT
Condition: Sarcoma
Intervention: Drug: 18F-FAZA
Sponsor: University Health Network, Toronto
Recruiting -
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
Posted: January 11th, 2017, 3:00pm GMT
Conditions: Alveolar Soft Part Sarcoma; Leiomyosarcoma; Synovial Sarcoma; Soft-Tissue Sarcoma
Interventions: Drug: AL3818; Drug: Dacarbazine; Drug: AL3818 or placebo
Sponsor: Advenchen Laboratories, LLC
Recruiting -
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
Posted: October 5th, 2016, 2:00pm GMT
Conditions: FNCLCC Sarcoma Grade 2; FNCLCC Sarcoma Grade 3; Resectable Leiomyosarcoma; Resectable Liposarcoma; Resectable Soft Tissue Sarcoma; Resectable Undifferentiated Pleomorphic Sarcoma; Soft Tissue Sarcoma of the Trunk and Extremities; Stage I Soft Tissue Sarcoma AJCC v7; Stage IA Soft Tissue Sarcoma AJCC v7; Stage IB Soft Tissue Sarcoma AJCC v7; Stage II Soft Tissue Sarcoma AJCC v7; Stage IIA Soft Tissue Sarcoma AJCC v7; Stage IIB Soft Tissue Sarcoma AJCC v7
Interventions: Radiation: Radiation Therapy; Biological: Talimogene Laherparepvec
Sponsor: National Cancer Institute (NCI)
Recruiting -
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Posted: September 14th, 2016, 2:00pm GMT
Condition: Diffuse Large B-cell Lymphoma
Intervention: Drug: MAK683
Sponsor: Novartis Pharmaceuticals
Recruiting -
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Posted: February 26th, 2016, 3:00pm GMT
Conditions: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Interventions: Drug: Crizotinib; Drug: Palbociclib; Drug: Sunitinib; Drug: Temsirolimus; Drug: Trastuzumab and Pertuzumab; Drug: Vemurafenib and Cobimetinib; Drug: Regorafenib; Drug: Olaparib; Drug: Pembrolizumab; Drug: Nivolumab and Ipilimumab; Drug: Abemaciclib; Drug: Afatinib; Drug: Talazoparib; Drug: Atezolizumab and PHESGO; Drug: Atezolizumab and Talazoparib; Drug: Entrectinib; Drug: Larotrectinib; Drug: Tucatinib plus Trastuzumab Subcutaneous (SC)
Sponsors: American Society of Clinical Oncology; AstraZeneca; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; Genentech, Inc.; Merck Sharp & Dohme Corp.; Pfizer; Boehringer Ingelheim; Seagen Inc.
Recruiting -
TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
Posted: January 15th, 2016, 3:00pm GMT
Condition: Sarcoma, Ewing
Intervention: Drug: TK216
Sponsor: Oncternal Therapeutics, Inc
Recruiting -
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
Posted: November 4th, 2015, 3:00pm GMT
Conditions: AIDS-Related Non-Hodgkin Lymphoma; Classic Hodgkin Lymphoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Hepatocellular Carcinoma; HIV Infection; Locally Advanced Lung Non-Small Cell Carcinoma; Locally Advanced Malignant Neoplasm; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Melanoma; Metastatic Neoplasm; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Recurrent Classic Hodgkin Lymphoma; Recurrent Kaposi Sarcoma; Refractory Classic Hodgkin Lymphoma; Refractory Kaposi Sarcoma; Refractory Neoplasm; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Melanoma
Interventions: Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
Posted: July 20th, 2015, 2:00pm GMT
Condition: Recurrent Osteosarcoma
Interventions: Biological: humanized anti-GD2 antibody; Drug: GM-CSF
Sponsors: Memorial Sloan Kettering Cancer Center; Children's Hospital Los Angeles; M.D. Anderson Cancer Center; Y-mAbs Therapeutics
Recruiting -
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
Posted: November 24th, 2014, 3:00pm GMT
Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Colorectal Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Ovarian Carcinoma; Metastatic Renal Cell Carcinoma; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Platinum-Resistant Ovarian Carcinoma; Recurrent Melanoma; Recurrent Renal Cell Carcinoma; Refractory Melanoma; Refractory Renal Cell Carcinoma; Sarcoma; Stage IV Colorectal Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8
Interventions: Biological: Pembrolizumab; Biological: Ziv-Aflibercept
Sponsor: National Cancer Institute (NCI)
Recruiting